These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26271493)

  • 21. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
    Little MH; Reitmeir P; Peters A; Leidl R
    Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A social preference valuations set for EQ-5D health states in Flanders, Belgium.
    Cleemput I
    Eur J Health Econ; 2010 Apr; 11(2):205-13. PubMed ID: 19582490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom.
    Galante J; Augustovski F; Colantonio L; Bardach A; Caporale J; Marti SG; Kind P
    Value Health; 2011; 14(5 Suppl 1):S60-4. PubMed ID: 21839901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in adults with cerebral palsy living in Sweden and relation to demographic and disability-specific factors.
    Jarl J; Alriksson-Schmidt A; Rodby-Bousquet E
    Disabil Health J; 2019 Jul; 12(3):460-466. PubMed ID: 30837198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What PASSes for good? Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade.
    Cooper A; Wallman JK; Gülfe A
    Scand J Rheumatol; 2016 Nov; 45(6):470-473. PubMed ID: 27025702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.
    Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
    Pharmacoeconomics; 2012 Dec; 30(12):1203-14. PubMed ID: 23116290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
    Karlsson JA; Nilsson JÅ; Neovius M; Kristensen LE; Gülfe A; Saxne T; Geborek P
    Ann Rheum Dis; 2011 Dec; 70(12):2163-6. PubMed ID: 21859684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets.
    Poteet S; Craig BM
    Patient; 2021 May; 14(3):339-345. PubMed ID: 33782840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system.
    Harrison MJ; Davies LM; Bansback NJ; McCoy MJ; Farragher TM; Verstappen SM; Hassell A; Symmons DP
    Value Health; 2009 Sep; 12(6):1026-34. PubMed ID: 19473335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences.
    Mulhern B; Bansback N; Hole AR; Tsuchiya A
    Med Decis Making; 2017 Apr; 37(3):285-297. PubMed ID: 27681988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease.
    Leidl R; Reitmeir P; König HH; Stark R
    Value Health; 2012 Jan; 15(1):151-7. PubMed ID: 22264983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the EQ-5D measure quality of life in schizophrenia?
    Halling Hastrup L; Nordentoft M; Hjorthøj C; Gyrd-Hansen D
    J Ment Health Policy Econ; 2011 Dec; 14(4):187-96. PubMed ID: 22345360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating an EQ-5D population value set: the case of Japan.
    Tsuchiya A; Ikeda S; Ikegami N; Nishimura S; Sakai I; Fukuda T; Hamashima C; Hisashige A; Tamura M
    Health Econ; 2002 Jun; 11(4):341-53. PubMed ID: 12007165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time trade-off and ranking exercises are sensitive to different dimensions of EQ-5D health states.
    Rand-Hendriksen K; Augestad LA
    Value Health; 2012; 15(5):777-82. PubMed ID: 22867789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
    Couzner L; Crotty M; Norman R; Ratcliffe J
    Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea.
    Jo MW; Yun SC; Lee SI
    Value Health; 2008 Dec; 11(7):1186-9. PubMed ID: 18489498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EQ-5D in Central and Eastern Europe: 2000-2015.
    Rencz F; Gulácsi L; Drummond M; Golicki D; Prevolnik Rupel V; Simon J; Stolk EA; Brodszky V; Baji P; Závada J; Petrova G; Rotar A; Péntek M
    Qual Life Res; 2016 Nov; 25(11):2693-2710. PubMed ID: 27472992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
    Noyes K; Dick AW; Holloway RG
    Med Decis Making; 2007; 27(3):327-34. PubMed ID: 17502449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.